See the DrugPatentWatch profile for dupixent
Does dupixent work for skin conditions?
Dupixent (dupilumab) works by blocking interleukin-4 and interleukin-13 signaling, two pathways that drive inflammation in certain skin diseases. The FDA first approved it for moderate-to-severe atopic dermatitis in adults in 2017 and later expanded approval to adolescents and children as young as 6 months.
How quickly do patients see results on the skin?
Most adults notice reduced itch within two weeks. Visible skin clearance typically appears between 4 and 16 weeks, with peak improvement often reached at 16 weeks. In clinical studies, roughly 36 % of adults achieved clear or almost-clear skin at week 16 compared with 9 % on placebo.
What skin conditions does Dupixent treat beyond eczema?
The drug is also approved for prurigo nodularis, a chronic condition marked by intensely itchy nodules. It is under review or in trials for chronic spontaneous urticaria, bullous pemphigoid, and alopecia areata, but these uses remain investigational.
How does Dupixent compare with topical steroids or JAK inhibitors?
Unlike topical steroids, Dupixent is injected every two weeks and targets a specific immune pathway, so it does not cause skin thinning. In head-to-head studies, it produced greater itch relief and skin clearance than high-potency topical steroids alone. Compared with oral JAK inhibitors, it shows fewer serious infections and no boxed warnings for cardiovascular events.
What side effects do patients report on the skin?
Conjunctivitis occurs in about 10 % of users and usually resolves with lubricating drops. Injection-site reactions, such as redness or swelling, affect 10–15 % of patients. Rare reports include facial redness or paradoxical worsening of eczema, prompting some patients to switch therapies.
When does the Dupixent patent expire?
The key U.S. composition-of-matter patent expires in 2027, with some formulation and method-of-use patents extending into 2032. [1] Biosimilar or interchangeable versions are unlikely before 2028.
DrugPatentWatch.com tracks these dates and related litigation.
Why are companies already challenging the Dupixent patents?
Several biosimilar makers filed paragraph-IV challenges in 2023 and 2024, arguing that certain method-of-use claims are obvious. The cases remain pending, and no generic entry is expected until at least 2027.
Can patients use Dupixent with other skin therapies?
Yes. Guidelines support combining it with topical moisturizers, calcineurin inhibitors, or short courses of topical steroids for flares. Long-term combination with systemic immunosuppressants is less common because Dupixent itself provides adequate control for most patients.
Who makes Dupixent and how much does it cost?
Sanofi and Regeneron jointly market the drug. Cash prices exceed $3,500 per carton (two pre-filled syringes), but most insured patients pay $0–$100 per month through copay assistance. Medicare Part D coverage varies by plan.
[1] https://www.drugpatentwatch.com/drug/dupixent